+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Fresenius Kabi AG - Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 57 Pages
  • August 2023
  • GlobalData
  • ID: 2870407
Fresenius Kabi AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - The publisher's summarization of the company's business strategy.
  • SWOT analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Fresenius Kabi AG (Fresenius Kabi), a wholly owned subsidiary of Fresenius SE & Co KGaA, develops, manufactures and commercializes pharmaceuticals products and medical devices. Its product portfolio includes intravenously administered drugs, infusion therapy products, medical devices and clinical nutrition products. The company's therapeutic expertise covers areas of blood volume substitution, fluid management, anesthesia, critical illness, liver insufficiency, renal insufficiency, maldigestion or malabsorption, diabetes mellitus and pediatrics. Its products and services are indicated for the treatment of critically and chronically ill patients. Fresenius Kabi conducts sales and marketing operations through direct offices worldwide. The company has its facilities in Europe, North America, Latin America, Asia Pacific and Africa. Fresenius Kabi is headquartered in Bad Homburg, Germany

Fresenius Kabi AG Key Recent Developments

  • May 17, 2023: Fresenius Kabi at the Euroanaesthesia 2023
  • May 15, 2023: Fresenius Kabi offers €100,000 grant to advance nutritional care in hospitalized patients
  • Feb 21, 2023: Fresenius with new strategy and clear focus
  • Jan 20, 2023: Healthcare Workers File Petition Asking FDA to Recall Fresenius Dialysis Machines to Protect Patients

Reasons to Buy

  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors' business structure and strategies with the publisher's detailed SWOT analysis. In this, the company's core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report's detailed insight into the company's strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Section 1 - About the Company
  • Fresenius Kabi AG - Key Facts
  • Fresenius Kabi AG - Key Employees
  • Fresenius Kabi AG - Key Employee Biographies
  • Fresenius Kabi AG - Major Products and Services
  • Fresenius Kabi AG - History
  • Fresenius Kabi AG - Company Statement
  • Fresenius Kabi AG - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Fresenius Kabi AG - Business Description
  • Business Segment: Clinical Nutrition
  • Overview
  • Performance
  • Business Segment: Infusion Therapy
  • Overview
  • Performance
  • Business Segment: IV Drugs
  • Overview
  • Performance
  • Business Segment: Medical Devices/Transfusion Technology
  • Overview
  • Performance
  • Geographical Segment: Asia-Pacific
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Latin America/Africa
  • Performance
  • Geographical Segment: North America
  • Performance
  • R&D Overview
  • Fresenius Kabi AG - Corporate Strategy
  • Fresenius Kabi AG - SWOT Analysis
  • SWOT Analysis - Overview
  • Fresenius Kabi AG - Strengths
  • Fresenius Kabi AG - Weaknesses
  • Fresenius Kabi AG - Opportunities
  • Fresenius Kabi AG - Threats
  • Fresenius Kabi AG - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • Fresenius Kabi AG, Medical Equipment, Deals By Year, 2017 to YTD 2023
  • Fresenius Kabi AG, Medical Equipment, Deals By Type, 2017 to YTD 2023
  • Fresenius Kabi AG, Recent Deals Summary
Section 4 - Company’s Recent Developments
  • May 17, 2023: Fresenius Kabi at the Euroanaesthesia 2023
  • May 15, 2023: Fresenius Kabi offers €100,000 grant to advance nutritional care in hospitalized patients
  • Feb 21, 2023: Fresenius with new strategy and clear focus
  • Jan 20, 2023: Healthcare Workers File Petition Asking FDA to Recall Fresenius Dialysis Machines to Protect Patients
  • Nov 16, 2022: Fresenius Kabi inaugurates extension of its production facilities in Haina
  • Oct 26, 2022: Fresenius Kabi employees around the world team up for breast cancer awareness
  • May 23, 2022: EuroPN Study: New clinical data on medical nutrition therapy in critically ill patients
  • May 04, 2022: Fresenius appoints Sara Hennicken as Chief Financial Officer - Rachel Empey to leave company at own request
  • Apr 18, 2022: Blood Centers across America unite to provide blood supplies to Ukraine
  • Mar 18, 2022: Update on Humanitarian aid for Ukraine
Section 5 - Appendix
  • Methodology
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Fresenius Kabi AG, Key Facts
  • Fresenius Kabi AG, Key Employees
  • Fresenius Kabi AG, Key Employee Biographies
  • Fresenius Kabi AG, Major Products and Services
  • Fresenius Kabi AG, History
  • Fresenius Kabi AG, Other Locations
  • Fresenius Kabi AG, Subsidiaries
  • Fresenius Kabi AG, Joint Venture
  • Fresenius Kabi AG, Key Competitors
  • Fresenius Kabi AG, Medical Equipment, Deals By Year, 2017 to YTD 2023
  • Fresenius Kabi AG, Medical Equipment, Deals By Type, 2017 to YTD 2023
  • Fresenius Kabi AG, Recent Deals Summary
List of Figures
  • Fresenius Kabi AG, Medical Equipment, Deals By Year, 2017 to YTD 2023
  • Fresenius Kabi AG, Medical Equipment, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Becton Dickinson and Co
  • Teva Pharmaceutical Industries Ltd
  • Sandoz Inc
  • Abbott Laboratories
  • Freya Global L.L.P
  • Charite Research Organisation GmbH
  • Baxter Healthcare Corp
  • Becton Dickinson and Co
  • Baxter Healthcare Corp
  • Freya Global L.L.P
  • Charite Research Organisation GmbH
  • Sandoz Inc
  • Teva Pharmaceutical Industries Ltd
  • Abbott Laboratories